

CMBI Credit Commentary

Fixed Income Daily Market Update 固定收益部市场日报

- *Asian IG space was stable with two-way flows this morning. HY LGFVs remained active. HRINTH curve down 0.25pt DALWANS/VNKRLEs were 0.1-0.2pt lower.*
- **MEDCIJ:** *USD107mn to be repurchased in the tender offers. Maintain buy on MEDCIJ'28/29. See below for comments.*
- **ADANIG/ADTIN:** *Adani Green Energy/Adani Energy Solutions 1H25 revenue rose 34.4%/57.6% yoy and EBITDA increased 20%/29.5% yoy. We have buy recommendation on ADANEM 3.867'31 within the Adani complex.*

❖ Trading desk comments 交易台市场观点

Yesterday, the recent new SEKIS 30/34 widened another 2-4bps. In KR, DAEECs were 2-3bps wider. HYUELEs/LGENSOs widened 2-5bps. In Chinese IGs, HAOHUA/TENCNT 28-30s were 1-3bps wider. WB/MEITUA/XIAOMI 30-31s widened 2-3bps. In financials, FRESHK 27s were 0.1pt lower (2-4bps wider), FRESHK 28s were 0.2pt lower (6bps wider). GRWALL Perp was 0.2pt lower. Meanwhile NSINTW '34 widened 2bps. BNKEA T2s 2-4bps wider. NANYAN '34/SHCMBK '33 were still under better buying and closed unchanged to 2bps tighter. In Insurance hybrids, MYLIFE '54/NIPLIF '54 were 0.3-0.7pt lower. ZURNVX '55 was 0.2pt lower. JP/AU AT1s such as MQGAU 6.125 Perp/MUFG 8.2 Perp/SOFTBK 6.6 Perp were down 0.1-0.3pt. In EU AT1s, BNP 7.375/INTNED 7.25/HSBC 6.95/LLOYDS 6.75/SOCGEN 8.5 Perps closed 0.3-0.5pt lower. In HK, CKINF/HYSAN/LIFUNG FFL Perps were down 0.2-0.5pt. Chinese properties were firm. FTLNHD/FUTLAN 25-26s rose 0.8-1.1pts. LNGFOR 28-32s/CHJMAO '29 were 0.2-0.4pt higher. In Macau gaming, MPELs/SANLTDs/STCITYs were 0.2-0.7pt lower. Outside China, GLPSP Perps dropped 0.7-0.9pt, GLPCHI '26/GLPSP '25 were down 0.3-0.4pt. In India, VEDLN 26-29s were unchanged to 0.2pt lower. See our comments [22 Oct '24](#). ADANEMs/ADSEZs/ADGREGs were 0.2-0.8pt lower. UPLLIN 28/30/Perp declined 0.4-0.6pt.

In LGFV, the flows were mixed. The quality LGFVs were better bid, whereas the high-yielding papers were subject to heavy selling pressure. CPDEV '25/BCDHGR '26/SIDEVE '26 were up 0.1pt. LYURBN '27/HNYUZI '26 were 0.2pt higher. CONSON '27/HKIQCL '27 were down 0.1-0.2pt. The CNH HSIVEH/GXDVIN 27s were 0.1pt lower. In SOE perps, SPICPF announced a new issue mandate of a NC3 Perp dollar bond. SPICPT 3.45 Perp/CHPWCN 4.25 Perp were up 0.2pt.

Glenn Ko, CFA 高志和
(852) 3657 6235
glennko@cmbi.com.hk

Cyrena Ng, CPA 吳倩瑩
(852) 3900 0801
cyrenang@cmbi.com.hk

Jerry Wang 王世超
(852) 3761 8919
jerrywang@cmbi.com.hk

❖ Last Trading Day's Top Movers

Top Performers	Price	Change	Top Underperformers	Price	Change
FUTLAN 4.45 07/13/25	89.4	1.1	INDON 4.2 10/15/50	85.0	-1.6
FTLNHD 4 5/8 10/15/25	84.9	0.8	INDON 5.65 01/11/53	103.8	-1.6
FTLNHD 4 1/2 05/02/26	76.7	0.8	INDON 5.45 09/20/52	101.2	-1.6
HAOHUA 4 3/4 06/19/49	90.7	0.8	INDON 4.35 01/11/48	87.9	-1.5
CITLTD 5.07 04/18/48	90.6	0.5	INDON 5.1 02/10/54	96.7	-1.5

❖ Marco News Recap 宏观新闻回顾

Macro – S&P (-0.05%), Dow (-0.02%) and Nasdaq (+0.18%) were mixed on Monday. UST yield edged higher yesterday, 2/5/10/30 yield reached 4.03%/4.00%/4.20%/4.49%.

❖ Desk Analyst Comments 分析员市场观点

➤ MEDCIJ: USD107mn to be repurchased in the tender offers. Maintain buy on MEDCIJ'28/29

Medco Energi (Medco) announced the results of the tender offers. It will accept to purchase a total of USD107.2mn in principle amount, i.e. USD57.1mn of MEDCIJ 7.375 05/14/26 at USD101.5, and USD50.1mn of MEDCIJ 6.375 01/30/27 at USD99.75. The total USD bonds outstanding of Medco would decrease by 7% to USD1.5bn after the settlement of the purchases on 24 Oct'24.

YTD, Medco issued 3 IDR bonds totaled cUSD96mn with maturity of 5-7 years, and the coupon rates ranging from 7.35- 8.5%. Meanwhile, Medco had cash on hand of USD663.5mn and ST debts of USD378.5mn at Jun'24. We expect Medco to continue to perform early redemptions through tender offers or calls given its sufficient liquidity and good access to fund channels. We maintain buy on MEDCIJs, and prefer MEDCIJ'28/29 for better risk-return profile within the curve. In the SEA space, we also like [ADANEM 3.867 07/22/31](#) as well as [INCLEN 4 ½ 04/18/27](#).

Table 1: Bond profile of MEDCIJ

Security Name	ISIN	Amt Out (USD mn)	Ask Px	YTM (Ask)	Rating(M/S/F)
MEDCIJ 7 ¾ 05/14/26	US58405FAA30	299.4	101.7	6.2	B1/BB-/BB-
MEDCIJ 6 ¾ 01/30/27	US58406LAA98	485.4	99.8	6.5	B1/BB-/BB-
MEDCIJ 6.95 11/12/28	US58406RAA68	299.4	99.8	7.0	B1/BB-/BB-
MEDCIJ 8.96 04/27/29	US58407HAA77	500.0	105.2	7.2	B1/BB-/BB-

Source: Bloomberg.

➤ Offshore Asia New Issues (Priced)

Issuer/Guarantor	Size (USD mn)	Tenor	Coupon	Priced	Issue Rating (M/S/F)
No Offshore Asia New Issues Priced Today					

➤ Offshore Asia New Issues (Pipeline)

Issuer/Guarantor	Currency	Size (USD mn)	Tenor	Pricing	Issue Rating (M/S/F)
Bank of Bukopin	USD	-	3yr	T+190	-/-/BBB

Bank of China Paris Branch	USD	-	3yr	SOFR+105	A1/A/A
Huzhou Moganshan Hi-tech Group	USD	-	3yr	5.7%	-/-/-
State Power Investment Corp	USD	-	PNC3	-	-/-/A-

➤ News and market color

- Regarding onshore primary issuances, there were 124 credit bonds issued yesterday with an amount of RMB114bn. As for month-to-date, 870 credit bonds were issued with a total amount of RMB792bn raised, representing a 5.4% yoy decrease
- **[ADANIG]** Adani Green Energy 1H25 total revenue rose 34.4% yoy to cUSD700mn and EBITDA from power supply rose 20% yoy to cUSD537mn
- **[ADTIN]** Adani Energy Solutions 1H25 revenue rose 57.6% yoy to cUSD1.38bn and EBITDA rose 29.5% yoy to cUSD435mn
- **[SOFTBK]** SoftBank-owned chip designer Arm said potential London listing not a priority
- **[SUNHUN]** Sun Hung Kai Properties announced USD10bn debt instruments issuance programme

Fixed Income Department

Tel: 852 3657 6235/ 852 3900 0801

fis@cmbi.com.hk

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Author Certification

The author who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the author covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that author in this report.

Besides, the author confirms that neither the author nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM and/or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

Disclaimer:

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.